Advertisement

Search Results

Advertisement



Your search for ASCO matches 14969 pages

Showing 101 - 150


multiple myeloma

FDA Approves Selinexor for Refractory or Relapsed Multiple Myeloma

On December 18, 2020, the U.S. Food and Drug Administration (FDA) approved selinexor (Xpovio) in combination with bortezomib (Velcade) and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. The FDA granted selinexor accelerated...

prostate cancer

FDA Approves First Oral Hormone Therapy for Treating Advanced Prostate Cancer

Today, the U.S. Food and Drug Administration (FDA) approved relugolix (Orgovyx) for the treatment of adult patients with advanced prostate cancer.  “Today’s approval marks the first oral drug in this class and it may eliminate some patients’ need to visit the clinic for treatments that require...

immunotherapy
leukemia
lymphoma

FDA Approves Rituximab-arrx, a Biosimilar to Rituximab

On December 17, the U.S. Food and Drug Administration (FDA) approved rituximab-arrx (Riabni), a biosimilar to rituximab (Rituxan), for the treatment of adult patients with non-Hodgkin lymphoma, chronic lymphocytic leukemia, granulomatosis with polyangiitis (Wegener's granulomatosis), and...

breast cancer

Sibylle Loibl, MD, on HR+ HER2– Primary Breast Cancer: Palbociclib and Endocrine Therapy

Sibylle Loibl, MD, of the German Breast Group, discusses the first phase III results from the PENELOPE-B study of palbociclib combined with endocrine therapy in patients with hormone receptor–positive, HER2-negative primary breast cancer who are at high risk for relapse after neoadjuvant...

breast cancer
genomics/genetics
immunotherapy

Joyce V. Lee, PhD, on Triple-Negative Breast Cancer: MYC as a Predictor of Treatment Response

Joyce V. Lee, PhD, of the University of California, San Francisco, discusses data that suggest the MYC oncogene may indicate whether a patient with triple-negative breast cancer will respond to immunotherapy. Dr. Lee’s study is the first to describe MYC downregulation of MHC-I and to demonstrate...

issues in oncology

Overcoming the Challenges of Addressing Race, Culture, and Structural Inequality in Medical Education

In 2017, a workgroup task force, made up of medical students and faculty at George Washington University, Texas Christian University, and the University of North Texas Health Science Center, conducted a literature review to identify best practices for teaching and learning about race and culture in ...

skin cancer
immunotherapy

ESMO Immuno-Oncology 2020: First-Line Anti–PD-1 Therapy vs BRAF/MEK Inhibition for Advanced BRAF V600–Mutated Melanoma

Findings from a propensity-matched survival analysis presented by van Breeschoten et al at the European Society for Medical Oncology (ESMO) Immuno-Oncology Virtual Congress 2020 (Abstract 37P) suggest that patients with advanced melanoma and a BRAF V600 mutation derive an enhanced survival benefit...

breast cancer

Roisin M. Connolly, MD, on HR+ Advanced Breast Cancer: Endocrine Therapy and Entinostat

Roisin M. Connolly, MD, of University College Cork, discusses phase III results from the E2112 trial, which showed exemestane plus entinostat did not improve survival in aromatase inhibitor–resistant advanced HR-positive, HER2-negative breast cancer (Abstract GS4-02).

Strict Adherence to Algorithm Required

A prospective cohort study found sentinel lymph node biopsy had a 96% sensitivity rate and a 99% negative predictive value for detecting nodal metastasis among patients with clinical stage I low-grade and high-grade endometrial cancer.1 “Our study suggests that [sentinel lymph node biopsy] has...

gynecologic cancers

Study Shows Sentinel Lymph Node Biopsy to Be 'Viable Option' for Surgical Staging of Endometrial Cancer

Sentinel lymph node biopsy “had similar diagnostic accuracy and prognostic ability as lymphadenectomy in patients with high-grade endometrial cancer at greatest risk for nodal metastases,” according to the SENTOR trial, a prospective cohort study of 156 patients with clinical stage I disease. Using ...

lung cancer
immunotherapy

ESMO Immuno-Oncology 2020: Sintilimab vs Docetaxel for Advanced Squamous NSCLC

Sintilimab provided superior clinical benefit compared to docetaxel in patients with previously treated, advanced and/or metastatic squamous non–small cell lung cancer (NSCLC), according to phase III study findings presented by Shi et al at the European Society for Medical Oncology (ESMO)...

breast cancer
immunotherapy

FDA Approves Margetuximab-cmkb Plus Chemotherapy for Previously Treated Patients With Metastatic HER2-Positive Breast Cancer

On December 16, the U.S. Food and Drug Administration (FDA) approved margetuximab-cmkb (Margenza) in combination with chemotherapy for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for...

leukemia
immunotherapy

Nitin Jain, MD, on B-Cell ALL: Expert Perspective on Key CAR T-Cell Treatment Advances

Nitin Jain, MD, of The University of Texas MD Anderson Cancer Center, reviews six important abstracts on CAR T-cell treatments for B-cell acute lymphoblastic leukemia (ALL): successful 24-hour manufacture of CAR T-cell therapy; ALLCAR19, a novel fast-off rate therapy; donor-derived CD19-targeted...

breast cancer

Lee S. Schwartzberg, MD, on HER2– HR+ Breast Cancer: Tesetaxel and Capecitabine

Lee S. Schwartzberg, MD, of the West Cancer Center, discusses phase III results from the CONTESSA study, which showed that an all-oral regimen of tesetaxel plus a reduced dose of capecitabine significantly improved progression-free survival compared with capecitabine alone in patients with...

breast cancer
immunotherapy

Sara A. Hurvitz, MD, on Triple-Negative Breast Cancer: Sacituzumab Govitecan and Chemotherapy

Sara A. Hurvitz, MD, of the David Geffen School of Medicine at UCLA, discusses phase III data from the ASCENT study of the antibody-drug conjugate sacituzumab govitecan vs chemotherapy in patients with previously treated metastatic triple-negative breast cancer (Abstract GS3-06).

breast cancer
supportive care

Patricia A. Ganz, MD, on Younger Breast Cancer Survivors: Managing Depression

Patricia A. Ganz, MD, of the University of California, Los Angeles, discusses study findings that showed mindfulness meditation and survivorship education may effectively reduce depression and related symptoms such as fatigue and sleep disturbance, which pose serious threats to younger women’s...

breast cancer

Joseph A. Sparano, MD, on HR+, HER2– Breast Cancer: Individualizing Prognosis and Predicting Treatment Success

Joseph A. Sparano, MD, of the Montefiore Medical Center and Albert Einstein College of Medicine, discusses the development and validation of a tool that integrates the 21-gene recurrence score and clinicopathologic features to individualize prognosis for distant recurrence and predict chemotherapy...

palliative care
symptom management

Reducing the Risk of Lymphedema in Patients With Cancer

Although the exact incidence of treatment-related lymphedema among cancer survivors is unknown—most likely due to its prolonged latency period—it can be a lifelong chronic side effect that negatively impacts survivors’ quality of life. Although the condition is often linked to treatment for breast...

skin cancer
immunotherapy

ESMO Immuno-Oncology 2020: Tebentafusp Shows Activity in Metastatic Uveal Melanoma

Tebentafusp is a novel bispecific molecule consisting of an affinity-enhanced T-cell receptor fused to an anti-CD3 effector that can redirect T cells to target gp100-positive cells. The agent showed clinical benefit, including target lesion reduction, in patients with metastatic uveal melanoma,...

breast cancer

Nadia Harbeck, MD, on Early Breast Cancer: Endocrine Therapy After Preoperative Treatment

Nadia Harbeck, MD, of the University of Munich, discusses the first outcome data from the phase III ADAPT HR+/HER– trial, which combined both static and dynamic biomarkers to optimize the adjuvant therapy approach in patients with intermediate- or high-risk luminal early breast cancer (Abstract...

leukemia

Farhad Ravandi, MD, on AML: Novel Combination Therapies for Newly Diagnosed Disease

Farhad Ravandi, MD, of The University of Texas MD Anderson Cancer Center, offers his expert perspective on key treatment studies in acute myeloid leukemia on the use of gilteritinib, consolidation chemotherapy, venetoclax, cladribine, azacitidine, quizartinib, decitabine, and CPX-351 (Session 616...

leukemia

Jorge E. Cortes, MD, on CML: Expert Perspective on Key ASH Abstracts

Jorge E. Cortes, MD, of the Georgia Cancer Center at Augusta University, reviews four important studies of treatment advances in chronic myeloid leukemia (CML): nilotinib vs dasatinib in newly diagnosed disease; final 5-year results from the BFORE trial on bosutinib vs imatinib for chronic phase...

leukemia

Hassan Awada, MD, on AML and Machine Learning: Improving Prognostication

Hassan Awada, MD, of the Taussig Cancer Institute, Cleveland Clinic Foundation, discusses the use of newer machine-learning techniques to help decipher a set of prognostic subgroups that could predict survival, thus potentially improving on traditional methods and moving acute myeloid leukemia into ...

bladder cancer
immunotherapy

ESMO Immuno-Oncology 2020: Adjuvant Atezoliumab for Patients With Muscle-Invasive Urothelial Cancer and Presence of Postsurgical ctDNA

Patients with muscle-invasive urothelial cancer and postsurgical circulating tumor DNA (ctDNA) positivity have high risk of disease recurrence following cystectomy and experienced improved clinical outcomes with adjuvant atezolizumab as compared to patients undergoing observation. These...

Eric P. Winer, MD, FASCO, Elected ASCO President for 2022–2023 Term

ASCO has elected Eric P. Winer, MD, FASCO, a longtime member and volunteer, to serve as its President for the term beginning in June 2022. He will take office as President-Elect during the ASCO Annual Meeting in June 2021. Five new members were also elected to the ASCO Board of Directors and the...

covid-19

FDA Authorizes Antigen Test as First Over-the-Counter, Fully At-Home Diagnostic Test for COVID-19

On December 15, the U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for the first over-the-counter, fully at-home diagnostic test for COVID-19. The Ellume COVID-19 Home Test is a rapid, lateral-flow antigen test, a type of test that runs a liquid sample along a...

issues in oncology

Trends in AYA Cancer Incidence in the United States Over 4 Decades

Cancer cases in adolescents and young adults (AYAs) have risen by 30% during the past 4 decades, with rates of kidney cancer increasing at the greatest rate, according to findings published by Scott et al in JAMA Network Open. The team said further research into screening, diagnosis, and treatment...

issues in oncology

Postoperative Cancer Surgery Mortality Rates Have Improved, but Gap Still Exists Between Black and White Patients

Mortality rates after cancer surgery declined for Black as well as White patients during a recent 10-year period, although the mortality gap between the two groups did not narrow, according to new research published by Miranda Lam, MD, MBA, and colleagues in JAMA Network Open. The findings present...

lymphoma

ASH 2020: ctDNA May Indicate Increased Risk of Relapse After Stem Cell Transplant in Patients With DLBCL

Many patients with diffuse large B-cell lymphoma (DLBCL) may be cured by autologous stem cell transplant, but as many as half eventually relapse. New research presented by Reid Merryman, MD, and colleagues at the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition suggests...

lung cancer
immunotherapy

ESMO Immuno-Oncology 2020: Does Pleural Effusion Affect Survival in Patients Treated With Immunotherapy for NSCLC?

Patients with non–small cell lung cancer (NSCLC) who have pleural effusion, especially those requiring pleural evacuation, experienced poorer survival when treated with immune checkpoint inhibitors, according to findings presented by Epaillard et al at the European Society for Medical Oncology...

breast cancer
immunotherapy

SABCS 2020: Patient-Reported Outcomes From the Phase III IMpassion031 Trial

Adding an immune checkpoint inhibitor to a standard chemotherapy regimen for patients with early-stage triple-negative breast cancer did not affect patients’ ability to perform day-to-day activities more than treatment with chemotherapy alone, according to research presented by Elizabeth...

covid-19

FDA Issues Emergency Use Authorization for First COVID-19 Vaccine

On December 11, the U.S. Food and Drug Administration (FDA) issued the first emergency use authorization (EUA) for a vaccine for the prevention of COVID-19 caused by SARS-CoV-2 in individuals aged 16 and older. The EUA allows the Pfizer-BioNTech COVID-19 vaccine to be distributed in the United...

lymphoma
immunotherapy

ASH 2020: Phase II ZUMA-12 Study Investigates First-Line Axicabtagene Ciloleucel for High-Risk Large B-Cell Lymphoma

The phase II ZUMA-12 trial found that axicabtagene ciloleucel, an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, is a safe and effective first-line therapy for patients with high-risk large B-cell lymphoma. These results were presented by Sattva S. Neelapu, MD, and colleagues...

breast cancer
survivorship

SABCS 2020: Can Mindfulness Meditation and Survivorship Education Help to Reduce Depression in Young Breast Cancer Survivors?

New research showed that behavioral interventions—mindfulness meditation and survivorship education classes—may be effective in reducing depressive symptoms in younger breast cancer survivors. This patient population often experiences the highest levels of depression, stress, and fatigue, which may ...

lymphoma
immunotherapy

Andrew D. Zelenetz, MD, PhD, on Mantle Cell Lymphoma: Expert Perspective on Key Clinical Trials

Andrew D. Zelenetz, MD, PhD, of Memorial Sloan Kettering Cancer Center, offers his expert views on five treatment studies in mantle cell lymphoma focusing on the next-generation BTK inhibitor LOXO-305; lisocabtagene maraleucel; minimal residual disease monitoring following autologous stem cell...

lymphoma
immunotherapy

Andrew D. Zelenetz, MD, PhD, on Mantle Cell Lymphoma: Immunochemotherapy Plus Lenalidomide

Andrew D. Zelenetz, MD, PhD, of Memorial Sloan Kettering Cancer Center, discusses phase II results from a single-center study that explored a novel approach for high-risk patients with mantle cell lymphoma. Among patients with TP53 wild-type disease, the data suggested this treatment was effective...

breast cancer

Debra A. Pratt, MD, on Time to Completion of Breast Cancer Treatment and Survival

In her recent study, Debra A. Pratt, MD, of the Cleveland Clinic, showed that when breast cancer treatment using any of three modalities takes longer than 38 weeks, it is associated with a decrease in survival, regardless of the receptor status. Patients with breast cancer who received neoadjuvant...

breast cancer

Chirag Shah, MD, on Assessing DCIS Recurrence Risk

Chirag Shah, MD, of the Cleveland Clinic, discusses the impact of DCISionRT testing on radiation therapy recommendations for patients with ductal carcinoma in situ following lumpectomy. His study found that despite using traditional favorable-risk criteria, radiation recommendations were changed in ...

multiple myeloma
immunotherapy

Meletios A. Dimopoulos, MD, on Multiple Myeloma: Daratumumab, Pomalidomide, and Dexamethasone

Meletios A. Dimopoulos, MD, of the University of Athens, discusses data from the phase III APOLLO study, which evaluated the use of subcutaneous daratumumab plus pomalidomide and dexamethasone, vs pomalidomide and dexamethasone alone, in patients with relapsed or refractory multiple myeloma...

lymphoma

Ari M. Melnick, MD, on Activated B-Cell­–Like DLBCL: Gain-of-Function Mutations and Resistance to Ibrutinib

Ari M. Melnick, MD, of Weill Cornell Medicine, discusses the BCL10 mutation in patients with activated B-cell–like diffuse large B-cell lymphoma, and his study results which showed that the mutation should be considered as a biomarker for ibrutinib resistance so that alternative targeted treatments ...

SITC Announces Creation of Steven A. Rosenberg, MD, PhD, Endowed Scholars Fund

The Society for Immunotherapy of Cancer (SITC) has announced the creation of the Steven A. Rosenberg, MD, PhD, Endowed Scholars Fund. Established in honor of Dr. Rosenberg, this fund recognizes his many contributions to the field by supporting investigators who are emerging leaders in...

Sara Federico, MD, Receives NCI Award for Leadership in Developing Clinical Trials for Pediatric Cancer

Sara Federico, MD, associate member of the Department of Oncology at St. Jude Children’s Research Hospital, has received the 2020 Cancer Clinical Investigator Team Leadership Award from the National Cancer Institute (NCI). This award recognizes and supports outstanding mid-career clinical...

2020 E. Donnall Thomas Lecture and Prize Awarded to Toshio Suda, MD, PhD

The American Society of Hematology (ASH) presented the 2020 E. Donnall Thomas Lecture and Prize to Toshio Suda, MD, PhD, of the National University of Singapore and Japan’s International Research Center for Medical Sciences, Kumamoto University, for his outstanding contributions to the field of...

2020 William Dameshek Prize Awarded to Adolfo Ferrando, MD, PhD

The American Society of Hematology (ASH) presented the 2020 William Dameshek Prize to Adolfo Ferrando, MD, PhD, of Columbia University Institute for Cancer Genetics in New York, for his outstanding research on the impact of NOTCH1 mutations on T-cell acute lymphoblastic leukemia (ALL). “I am...

ASH Awards Henry M. Stratton Medal to Hematology Researchers

The American Society of Hematology (ASH) recognized Michelle Le Beau, PhD, of the University of Chicago and the University of Chicago Medicine Comprehensive Cancer Center, and Maria Domenica Cappellini, MD, of the University of Milan in Italy, with the 2020 Henry M. Stratton Medal for their...

New Rules on Health-Care Price Transparency and Coverage for COVID-19 Vaccines

ON OCTOBER 28, the U.S. Department of Health and Human Services (HHS), the U.S. Department of Labor, and the U.S. Department of the Treasury released the coverage transparency final rule. Building on earlier administration actions requiring hospitals to disclose standard charges and negotiated...

Shilpi Gupta, MD, Joins Atlantic Health System Cancer Care’s Comprehensive Breast Health Program

Atlantic Health System Cancer Care recently announced that fellowship-trained medical oncologist Shilpi Gupta, MD, has joined Morristown Medical Center’s comprehensive breast health program, where her focus is breast oncology and research. Dr. Gupta is on staff at Atlantic Hematology Oncology at...

Albert Einstein College of Medicine Researchers Receive $5 Million Grant From the National Institutes of Health

A TEAM OF SCIENTISTS from Albert Einstein College of Medicine has received a 5-year, $4.9 million grant from the National Institutes of Health (NIH) to establish a research center to investigate human immunodeficiency virus (HIV)- and human papillomavirus (HPV)-related cancers in Africa. The...

City of Hope Orange County Names Edward S. Kim, MD, MBA, Its Physician-in-Chief

CITY OF HOPE ORANGE COUNTY recently announced the appointment of cancer researcher and clinician Edward S. Kim, MD, MBA, as Senior Vice President and Vice Physician-in-Chief at City of Hope and Orange County Physician-in-Chief. “Dr. Kim has a depth and breadth of cancer expertise that is well...

Abraham Chachoua, MD, Announced as New Director of Perlmutter Cancer Center’s Lung Cancer Center

New York University (NYU) Langone Health’s Perlmutter Cancer Center recently appointed Abraham Chachoua, MD, as the new Director of Perlmutter Cancer Center’s Lung Cancer Center. Dr. Chachoua currently serves as the Jay and Isabel Fine Professor of Oncology and Professor of Urology at NYU...

Advertisement

Advertisement



Advertisement